Title:Clinical Development of Oncolytic Viruses in China
Volume: 13
Issue: 9
Author(s): Min Liang
Affiliation:
Keywords:
Oncolytic Viruses, cancer, nasopharyngeal carcinoma, GM-CSF, efficacy
Abstract: The oncolytic virus, being a promising new therapeutic strategy for cancer, has inspired a wave of recent clinical
research and development in China. The first commercialized oncolytic virus, Oncorine, was approved by Chinese
SFDA in November 2005 for nasopharyngeal carcinoma combined with chemotherapy. Since then, a number of oncolytic
viruses have been moved into clinical trials. Among these are the armed oncolytic adenoviruses such as H103 (expressing
the heat shock protein) currently has finished phase I trial, and KH901 (expressing GM-CSF) now launched in phase II
trial In this review, we will discuss the current status of ongoing oncolytic virus projects being conducted at various clinical
stages in China, including the preliminary market response for Oncorine after it was launched into the Chinese market
in 2006.